- Home
- ACLX
ACLX
Arcellx Inc.
as of 03-06-2026 3:38pm EST
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 3.7B | IPO Year: | 2022 |
| Target Price: | $115.85 | AVG Volume (30 days): | 3.5M |
| Analyst Decision: | Hold | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.07 | EPS Growth: | -103.50 |
| 52 Week Low/High: | $47.86 - $114.65 | Next Earning Date: | N/A |
| Revenue: | $22,286,000 | Revenue Growth: | -79.35% |
| Revenue Growth (this year): | 329.4% | Revenue Growth (next year): | 151.37% |
| P/E Ratio: | -28.13 | Index: | N/A |
| Free Cash Flow: | -212585000.0 | FCF Growth: | N/A |
AI-Powered ACLX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Arcellx Inc. (ACLX)
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$113.82
Shares
11,219
Total Value
$1,276,954.43
Owned After
33,938
SEC Form 4
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$68.56
Shares
8,384
Total Value
$572,567.86
Owned After
33,938
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$69.61
Shares
11,291
Total Value
$784,782.63
Owned After
33,938
Director
Avg Cost/Share
$75.00
Shares
6,000
Total Value
$450,000.00
Owned After
21,659
SEC Form 4
CHIEF MEDICAL OFFICER
Avg Cost/Share
$68.51
Shares
5,882
Total Value
$402,997.00
Owned After
23,749
SEC Form 4
CHIEF MEDICAL OFFICER
Avg Cost/Share
$65.51
Shares
7,437
Total Value
$487,212.74
Owned After
23,749
SEC Form 4
CHIEF MEDICAL OFFICER
Avg Cost/Share
$64.15
Shares
6,131
Total Value
$393,285.87
Owned After
23,749
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Feb 25, 2026 | Sell | $113.82 | 11,219 | $1,276,954.43 | 33,938 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Feb 19, 2026 | Sell | $68.56 | 8,384 | $572,567.86 | 33,938 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Feb 17, 2026 | Sell | $69.61 | 11,291 | $784,782.63 | 33,938 | |
| Lubner David Charles | ACLX | Director | Jan 20, 2026 | Sell | $75.00 | 6,000 | $450,000.00 | 21,659 | |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Jan 14, 2026 | Sell | $68.51 | 5,882 | $402,997.00 | 23,749 | |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Jan 13, 2026 | Sell | $65.51 | 7,437 | $487,212.74 | 23,749 | |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Jan 12, 2026 | Sell | $64.15 | 6,131 | $393,285.87 | 23,749 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K BUY Nov 5, 2025 · 100% conf.
Q3 2025 Earnings
8-K BUYNov 5, 2025 · 100% conf.
1D
+5.98%
$92.74
5D
+7.86%
$94.39
20D
+9.40%
$95.74
8-K
false000178620500017862052025-11-052025-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 05, 2025
Arcellx, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-41259
47-2855917
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
800 Bridge Parkway
Redwood City, California
94065
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 240 327-0630
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
ACLX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 5, 2025, Arcellx, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended September 30, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information furnished pursuant to Item 2.02 on this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.
Description
99.1
Press Release dated November 5, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL Document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Arcellx, Inc.
Date:
November 5, 2025
By:
/s/ Rami Elghandour
Rami Elghandour Chief Executive Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
Q2 2025 Earnings
8-KAug 7, 2025
8-K
0001786205false00017862052025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 07, 2025
Arcellx, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-41259
47-2855917
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
800 Bridge Parkway
Redwood City, California
94065
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 240 327-0630
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
ACLX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 7, 2025, Arcellx, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended June 30, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information furnished pursuant to Item 2.02 on this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.
Description
99.1
Press Release dated August 7, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL Document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Arcellx, Inc.
Date:
August 7, 2025
By:
/s/ Rami Elghandour
Rami Elghandour Chief Executive Officer
2025 Q1 Q1 2025 Earnings
8-K May 8, 2025
Q1 2025 Earnings
8-KMay 8, 2025
8-K
false 0001786205 0001786205 2025-05-08 2025-05-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025
Arcellx, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-41259
47-2855917
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
800 Bridge Parkway Redwood City, CA 94065 (Address of principal executive offices, including zip code) (240) 327-0630 (Registrant’s telephone number, including area code) Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
ACLX
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 8, 2025, Arcellx, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended March 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to Item 2.02 on this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press Release dated May 8, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL Document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Arcellx, Inc.
Date: May 8, 2025
By:
/s/ Rami Elghandour
Rami Elghandour Chief Executive Officer
Compare ACLX vs Leading Stocks
See how ACLX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ACLX Arcellx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.